[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565746":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":49,"centralContacts":53,"locations":62,"responsibleParty":124,"collaborators":127,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":143,"sex":144,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":40,"studyType":150,"phases":151,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":65,"whyStopped":40,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},{"fullName":5,"class":6},"Swiss Tropical & Public Health Institute","OTHER",[8,15,19,23,27,31],{"label":9,"type":6,"description":10,"interventionNames":11},"TamponCupPad","Participants will adopt tampons during the first two menstrual cycles (first period of the trial), followed by adoption of cups during the next two menstrual cycles (second period), and lastly menstrual pads for the next two menstrual cycles (third crossover period).",[12,13,14],"Other: Menstrual Pads","Other: Menstrual Cups","Other: Tampons",{"label":16,"type":6,"description":17,"interventionNames":18},"TamponPadCup","Participants will adopt tampons during the first two menstrual cycles (first period of the trial), followed by adoption of pads during the next two menstrual cycles (second period), and lastly menstrual cups for the next two menstrual cycles (third crossover period).",[12,13,14],{"label":20,"type":6,"description":21,"interventionNames":22},"CupTamponPad","Participants will adopt menstrual cups during the first two menstrual cycles (first period of the trial), followed by adoption of tampons during the next two menstrual cycles (second period), and lastly menstrual pads for the next two menstrual cycles (third crossover period).",[12,13,14],{"label":24,"type":6,"description":25,"interventionNames":26},"CupPadTampon","Participants will adopt menstrual cups during the first two menstrual cycles (first period of the trial), followed by adoption of menstrual pads during the next two menstrual cycles (second period), and lastly tampons for the next two menstrual cycles (third crossover period).",[12,13,14],{"label":28,"type":6,"description":29,"interventionNames":30},"PadTamponCup","Participants will adopt menstrual pads during the first two menstrual cycles (first period of the trial), followed by adoption of tampons during the next two menstrual cycles (second period), and lastly menstrual cups for the next two menstrual cycles (third crossover period).",[12,13,14],{"label":32,"type":6,"description":33,"interventionNames":34},"PadCupTampon","Participants will adopt menstrual pads during the first two menstrual cycles (first period of the trial), followed by adoption of menstrual cups during the next two menstrual cycles (second period), and lastly tampons for the next two menstrual cycles (third crossover period).",[12,13,14],[36,41,45],{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Menstrual Pads","Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.",[24,20,32,28,9,16],null,{"type":6,"name":42,"description":43,"armGroupLabels":44,"otherNames":40},"Menstrual Cups","Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.",[24,20,32,28,9,16],{"type":6,"name":46,"description":47,"armGroupLabels":48,"otherNames":40},"Tampons","Participants adopt tampons to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.",[24,20,32,28,9,16],[50],{"name":51,"affiliation":5,"role":52},"Sonja Merten, PhD","PRINCIPAL_INVESTIGATOR",[54,59],{"name":55,"role":56,"phone":57,"phoneExt":40,"email":58},"Sonja Merten, MD MPH PhD","CONTACT","0041-61-284-8387","sonja.merten@swisstph.ch",{"name":60,"role":56,"phone":57,"phoneExt":40,"email":61},"Monica Ticlla, PhD","monicaroxana.ticllaccenhua@swisstph.ch",[63,85,108],{"facility":64,"status":65,"city":66,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Centre de Recherche sur les Maladies Emergentes et Re-Emergentes","RECRUITING","Yaoundé","3","Cameroon","CM",{"type":71,"coordinates":72},"Point",[73,74],11.51667,3.86667,{"lat":74,"lon":73},[77,81],{"name":78,"role":56,"phone":79,"phoneExt":40,"email":80},"Esemu Livo, PhD","+237 674 632 078","esemu_livo@yahoo.com",{"name":82,"role":56,"phone":83,"phoneExt":40,"email":84},"Marie Josiane Kenfack, PhD(c)","+237676783165","kenfackjosiane@yahoo.fr",{"facility":86,"status":65,"city":87,"state":87,"zip":88,"country":89,"countryCode":90,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Universidad Nacional de la Amazonia Peruana","Iquitos","16007","Peru","PE",{"type":71,"coordinates":92},[93,94],-73.2529,-3.74814,{"lat":94,"lon":93},[97,101,105],{"name":98,"role":56,"phone":99,"phoneExt":40,"email":100},"Viviana Pinedo, PhD","+51 955 850 853","viviana.pinedo@unapiquitos.edu.pe",{"name":102,"role":56,"phone":103,"phoneExt":40,"email":104},"Sandra Condori, PhD","+32 488 15 54 52","sandra.condori@uantwerpen.be",{"name":106,"role":107,"phone":40,"phoneExt":40,"email":40},"Katty Arista, M.Sc","SUB_INVESTIGATOR",{"facility":109,"status":65,"city":110,"state":110,"zip":111,"country":112,"countryCode":113,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Swiss Tropical and Public Health Institute","Allschwil","4123","Switzerland","CH",{"type":71,"coordinates":115},[116,117],7.53599,47.55074,{"lat":117,"lon":116},[120,122],{"name":55,"role":56,"phone":121,"phoneExt":40,"email":58},"+41 79 640 17 27",{"name":60,"role":56,"phone":40,"phoneExt":40,"email":123},"monicaroxana.ticllaccenhua@unibas.ch",{"type":52,"investigatorFullName":125,"investigatorTitle":126,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Sonja Merten","Head of Unit Society, Gender and Health",[128,130,132,133],{"name":86,"class":129},"UNKNOWN",{"name":131,"class":6},"Universidad Peruana Cayetano Heredia",{"name":64,"class":129},{"name":134,"class":6},"Universiteit Antwerpen","100565746","improving-menstrual-and-vaginal-health-for-all-100565746",false,"NCT06646185","Improving Menstrual and VAginal Health for All","IMVAHA: Improving Menstrual and VAginal Health for All","IMVAHA","Inclusion Criteria:\n\n* able to provide informed consent;\n* aged 18-35;\n* residing in the recruitment region and expecting to reside in the same region for at least six months following recruitment (Yaoundé\u002F Gounougou, Cameroon; Loreto\u002FLima\u002FMaynas provinces, Peru; or Basel-Landschaft and Basel-Stadt cantons, Switzerland);\n* are native speakers or are able to read and understand one of the following languages in each respective country (German, French, Italian, English or Spanish in Switzerland; French or English in Cameroon; Spanish in Peru);\n* had menstrual cycles of 21-35 days for at least the last 4 months;\n* had menses which lasted at least 3 days for at least the last 4 months.\n\nExclusion criteria:\n\n* experienced a menstrual abnormality with any of the menstrual cycles in the last 4 months (such as oligomenorrhea or amenorrhea, or bleed more than 7 days a month);\n* are pregnant or actively trying to become pregnant;\n* are breastfeeding;\n* used antibiotics and\u002For vaginal antifungals in the last 30 days prior to recruitment;\n* had a vaginal birth in the last 6 months;\n* vaginal surgery, perineal surgery, uterine surgery, miscarriage or abortion in the last 6 months;\n* history of Toxic Shock Syndrome ;\n* positive to detection of the toxic shock syndrome toxin-1 gen (tst) using Polymerase Chain Reaction (PCR);\n* Intrauterine device in situ;\n* under medication (treatment against infectious or chronic disease) at the time of recruitment or during the 3 weeks prior to recruitment;\n* clinical symptoms of vaginal infection;\n* smoker.",true,"FEMALE","18 Years","35 Years",{"count":148,"type":149},100,"ESTIMATED","INTERVENTIONAL",[152],"NA","A three-period crossover trial will study the effects of short-term use of 3 menstrual products (menstrual pad, tampon, menstrual cup) on the bacterial composition of the vaginal microbiome in three countries (Peru, Cameroon, and Switzerland). Each crossover period consists of two menstrual cycles, thus resulting in a 6-month trial. Participants will be randomly assigned to one of 6 exposure sequences (different order of products per sequence); in each sequence, participants will adopt each menstrual product for 2 menstrual cycles. Participants will provide vaginal microbiome samples via self-sample swabs at 3 points during each menstrual cycle. Given the crossover design of the study, there is not a dedicated control group.",[155],"Effects of Menstrual Products on the Vaginal Microbiome",[157,158,159,160],"vaginal microbiome","menstruation","crossover study","menstrual products","2026-04-20",{"date":163,"type":164},"2026-04-23","ACTUAL",{"date":166,"type":164},"2026-04-15",{"date":168,"type":149},"2026-12-31",{"name":5,"class":6},3]